Wegovy for fatty liver disease (MASH/NAFLD)

Off-label for fatty liver disease (MASH/NAFLD)
Medically reviewed by Jane Novak, MD, MPH, MD, MPH · Endocrinology · Internal Medicine 3 min read

The short answer

No GLP-1 is yet FDA-approved for fatty liver disease, but semaglutide has strong MASH trial data and is prescribed off-label, often through an obesity or diabetes pathway.

Wegovy specifically

Off-label for MASH; on-label for obesity, which is the usual qualifying route.

BMI & eligibility

Coverage runs through obesity or type 2 diabetes; fatty liver disease itself is not a covered GLP-1 indication as of 2026.

Check your BMI

BMI calculator

Overweight27.7

BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).

BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.

Insurance & coverage

No insurer covers a GLP-1 for fatty liver directly. Document obesity or diabetes for prior authorization. This may change if the FDA approves semaglutide for MASH.

Check if your plan covers it

We earn affiliate commissions from listed providers. See our editorial standards.

Other GLP-1s for fatty liver disease (MASH/NAFLD)

GLP-1 medications for fatty liver disease (MASH/NAFLD)Ozempic for fatty liver disease (MASH/NAFLD)Zepbound for fatty liver disease (MASH/NAFLD)Mounjaro for fatty liver disease (MASH/NAFLD)

Wegovy for other conditions

Wegovy for PCOSWegovy for prediabetesWegovy for insulin resistanceWegovy for obstructive sleep apneaWegovy for type 2 diabetesWegovy for obesity

See all GLP-1 eligibility guides

Sources

Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.